Denileukin diftitox: A concise clinical review

John W. Eklund; Timothy M. Kuzel

doi:10.1586/14737140.5.1.33

Denileukin diftitox: A concise clinical review

John W. Eklund, Timothy M. Kuzel^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Review article › peer-review

54 Scopus citations

Abstract

Denileukin diftitox (DAB₃₈₉IL-2; Ontak®) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma. It consists of fragments of diphtheria toxin linked to human interleukin-2 and works by targeting the high-affinity interleukin-2 receptor expressed on malignant cells. This article will review the clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma, and discuss the potential future role of this novel drug in patients with both malignant and nonmalignant diseases, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, solid tumors, psoriasis and graft-versus-host disease.

Original language	English (US)
Pages (from-to)	33-38
Number of pages	6
Journal	Expert review of anticancer therapy
Volume	5
Issue number	1
DOIs	https://doi.org/10.1586/14737140.5.1.33
State	Published - Feb 2005

Keywords

Cutaneous T-cell lymphoma
DABIL-2
Denileukin diftitox
Diphtheria toxin
Fusion protein
Ontak®

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/14737140.5.1.33

Cite this

@article{ffdd4587638743dfbe3308a7e998706a,

title = "Denileukin diftitox: A concise clinical review",

abstract = "Denileukin diftitox (DAB389IL-2; Ontak{\textregistered}) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma. It consists of fragments of diphtheria toxin linked to human interleukin-2 and works by targeting the high-affinity interleukin-2 receptor expressed on malignant cells. This article will review the clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma, and discuss the potential future role of this novel drug in patients with both malignant and nonmalignant diseases, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, solid tumors, psoriasis and graft-versus-host disease.",

keywords = "Cutaneous T-cell lymphoma, DABIL-2, Denileukin diftitox, Diphtheria toxin, Fusion protein, Ontak{\textregistered}",

author = "Eklund, {John W.} and Kuzel, {Timothy M.}",

year = "2005",

month = feb,

doi = "10.1586/14737140.5.1.33",

language = "English (US)",

volume = "5",

pages = "33--38",

journal = "Expert review of anticancer therapy",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "1",

}

TY - JOUR

T1 - Denileukin diftitox

T2 - A concise clinical review

AU - Eklund, John W.

AU - Kuzel, Timothy M.

PY - 2005/2

Y1 - 2005/2

N2 - Denileukin diftitox (DAB389IL-2; Ontak®) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma. It consists of fragments of diphtheria toxin linked to human interleukin-2 and works by targeting the high-affinity interleukin-2 receptor expressed on malignant cells. This article will review the clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma, and discuss the potential future role of this novel drug in patients with both malignant and nonmalignant diseases, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, solid tumors, psoriasis and graft-versus-host disease.

AB - Denileukin diftitox (DAB389IL-2; Ontak®) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma. It consists of fragments of diphtheria toxin linked to human interleukin-2 and works by targeting the high-affinity interleukin-2 receptor expressed on malignant cells. This article will review the clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma, and discuss the potential future role of this novel drug in patients with both malignant and nonmalignant diseases, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, solid tumors, psoriasis and graft-versus-host disease.

KW - Cutaneous T-cell lymphoma

KW - DABIL-2

KW - Denileukin diftitox

KW - Diphtheria toxin

KW - Fusion protein

KW - Ontak®

UR - http://www.scopus.com/inward/record.url?scp=14244262178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14244262178&partnerID=8YFLogxK

U2 - 10.1586/14737140.5.1.33

DO - 10.1586/14737140.5.1.33

M3 - Review article

C2 - 15757436

AN - SCOPUS:14244262178

SN - 1473-7140

VL - 5

SP - 33

EP - 38

JO - Expert review of anticancer therapy

JF - Expert review of anticancer therapy

IS - 1

ER -

Denileukin diftitox: A concise clinical review

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this